Weekly Digest – May 2026 Weekly Digest – May 2026 07 May 2026: Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza Bristol Myers Squibb has expanded its ADC strategy through an exclusive licensing agreement with Lonza, gaining access to […]
Weekly Digest – May 2026 Weekly Digest – May 2026 06 May 2026: Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program Waiv, formerly known as Owkin Dx, has entered a new collaboration with Daiichi Sankyo […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic Tacalyx announced the selection of its first clinical candidate, TCX-201, an antibody drug conjugate […]
Weekly Digest – April 2026 Weekly Digest – April 2026 23 April 2026: Servier completes the acquisition of Day One Biopharmaceuticals Servier has completed the acquisition of Day One Biopharmaceuticals in a deal valued at approximately $2.5 billion, strengthening its […]
Weekly Digest – April 2026 Weekly Digest – April 2026 14 April 2026: CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs CrossBridge Bio, Inc. has entered into a definitive agreement to be […]
Weekly Digest – April 2026 Weekly Digest – April 2026 10 April 2026: 3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development 3B Pharmaceuticals GmbH and TetraKit Technologies have entered into a strategic collaboration to […]
Weekly Digest – April 2026 Weekly Digest – April 2026 06 April 2026: Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC payload targeting RNA splicing Akari Therapeutics has entered into a strategic partnership […]
Weekly Digest – April 2026 Weekly Digest – April 2026 08 April 2026: Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer Sidewinder Therapeutics has secured $137 million in an oversubscribed […]
Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy Zai Lab […]
Weekly Digest – April 2026 Weekly Digest – April 2026 31 March 2026: NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development NJ Bio and Ajinomoto Bio-Pharma Services have entered into a research collaboration to expand […]
